Last reviewed · How we verify
NE3107
NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system.
NE3107 is a small-molecule inhibitor of translocator protein (TSPO) that crosses the blood-brain barrier to reduce neuroinflammation and oxidative stress in the central nervous system. Used for Alzheimer's disease, Parkinson's disease.
At a glance
| Generic name | NE3107 |
|---|---|
| Also known as | bezisterim |
| Sponsor | BioVie Inc. |
| Drug class | TSPO inhibitor |
| Target | TSPO (translocator protein, 18 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
NE3107 targets the 18 kDa translocator protein (TSPO), which is upregulated in activated microglia and astrocytes during neuroinflammatory conditions. By inhibiting TSPO, the drug reduces mitochondrial dysfunction and neuroinflammatory signaling, thereby decreasing oxidative stress and neuronal damage. This mechanism is intended to slow neurodegeneration in conditions characterized by chronic neuroinflammation.
Approved indications
- Alzheimer's disease
- Parkinson's disease
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- NE3107 in Adults With Neurological Symptoms of Long COVID (PHASE2)
- Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury (PHASE2)
- A Study of NE3107 in Early Parkinson's (PHASE2)
- Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia (PHASE2)
- A Phase 3 Study of NE3107 in Probable Alzheimer's Disease (PHASE3)
- NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NE3107 CI brief — competitive landscape report
- NE3107 updates RSS · CI watch RSS
- BioVie Inc. portfolio CI